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1. Introduction 
There is a strong relationship between hypertension and Chronic Kidney Disease (CKD). 
Hypertension is an important cause of End-Stage Renal Disease (ESRD), contributing to the 
disease itself or, most commonly, contributing to its progression. On the other hand, 
hypertension is highly prevalent in CKD patients, playing a role in the high cardiovascular 
morbidity and mortality of this particular population. This chapter will focus on the 
pathogenesis of hypertension-related CKD and its role on the progression of renal disease 
itself. The pathogenesis and treatment of hypertension resulting from CKD will also be 
addressed. 
2. Hypertension as a cause of CKD 
The relationship between abnormal blood pressure and kidney dysfunction was first 
established in the 19th century. The prevalence of both, and of the associated burden of 
cardiovascular morbidity and mortality, has been dramatically increasing worldwide 
(Kearney et al., 2005; Kearney et al., 2004; Ong et al., 2007; Schoenborn & Heyman, 2009; 
USRDS 2010; Meguid El Nahas & Bello, 2005). Data from several renal databases identifies 
systemic hypertension as the second most common cause of ESRD, with Diabetes mellitus 
being the first. In the United States (US), hypertension is the leading cause of ESRD in 
African-American patients (USRDS 2010; Klag et al., 1996; Hsu et al., 2005). Additionally, for 
any given cause of CKD, the elevation in systemic blood pressure accelerates the rate at 
which the glomerular filtration rate (GFR) declines (Perry et al., 1995). This is particularly 
true for patients with proteinuric nephropathies (Jafar et al., 2003). 
2.1 Pathogenesis of hypertensive renal damage 
The exact mechanisms of kidney damage in patients with hypertension still remain elusive. 
Two complementary pathogenic mechanisms ultimately ending in kidney fibrosis and 
scarring have been proposed. One starts with the changes in systemic and renal macro and 
microvasculature leading to the loss of renal auto-regulation with elevation of 
intraglomerular capillary pressure and the consequent hyperfiltration-mediated injury. 
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Hyperfiltration leads to transglomerular loss of proteins which promotes the release of 
cytokines and growth factors by mesangial cells and downstream tubular epithelial cells. 
The second mechanism proposes endothelial dysfunction and loss of endogenous 
vasodilators as precipitating factors of hypoxic-ischemic injury. The consequent activation of 
the intrarrenal Renin Angiotensin System (RAS) and the increased release of cytokines and 
growth factors with recruitment of inflammatory cells stimulate apoptosis causing loss of 
normal kidney cells and increased matrix production, finally leading to progressive 
glomerular and interstitial fibrosis and scarring. 
Evidence to support, this apparently straightforward, chain of events starting in systemic 
hypertension and culminating in ESRD, has been accumulating since the beginnings of the 
20th century when Goldblatt conducted his first experiments in dogs driven hypertensive by 
the clipping of one renal artery: the two-kidney one clip model of hypertension (Goldblatt, 
1964). The brilliancy of this model rests on the existence of a control organ: the clipped 
kidney was protected from the deleterious effects of blood pressure. In fact, vascular 
damage was not found in the clipped kidneys. More recently, other authors reported that 
the clipped kidney is also protected from the effects of immunological mediators (Wenzel et 
al., 2002).  
Extension of this model to rats and rabbits confirmed Goldblatt findings ( Eng et al., 1994; 
Wenzel et al., 2002). These later experiments also documented the pivotal role of changes in 
renal macro and microvasculature to induce and maintain a vicious cycle, where 
hypertension causes vascular lesions which in turn will further increase blood pressure, 
even after its primary cause has been removed (Rettig et al., 1990).  
Further investigation on animal models, as well as on genetic models of hypertension, 
allowed the description of three different stages of preglomerular vascular change. The 
histopathological resemblance between these experimentally induced vascular lesions and 
those observed in benign and malignant nephrosclerosis in human kidneys have long been 
documented.  Medial thickening with narrowing of the lumen resulting from hypertrophy 
of smooth muscle cells (Nordborg et al., 1983; Hampton et al., 1989; Vial & Boyd 1989; Lee, 
1987; Mulvany & Aalkjaar 1990; Owens & Schartz, 1982; Chobanian et al., 1984; Ross, 1993) 
is followed by segmental hyalinosis of the vessel wall of interlobular arteries and afferent 
arterioles. In humans studies using light microscopy and imunofluorescence these lesions 
were better characterized and termed “benign nephrosclerosis” (Valenzuela, 1980; 
Fisher,1966). Finally, the most severe type of hypertensive renal vascular lesion, similar to 
“malignant nephrosclerosis”, is proliferation of the intima resulting in the typical onion-like 
appearance and extremely narrow vessels predominantly affecting the interlobular arteries 
and afferent arterioles (Klemperer & Otani, 1931). The previous existence of medial 
hypertrophy and, or, increased collagen content in the arterial wall were pre-requisites for 
the development of this final stage (Helmchen et al., 1984, Bidani et al., 1994). However, in 
humans even the early lesions of malignant nephrosclerosis affect the intima (Ellis, 1942; 
Heptinstal, 1953; Somers, 1958).  
After this initial chain of events, increased glomerular perfusion and elevation of glomerular 
capillary pressure resulting in hyperfiltration, lead to further damage of the affected 
glomerulus (Brenner, 1985; Klahr et al., 1988) and to increased filtration of proteins to the 
tubular lumen. Enhanced tubular reabsorption induces the synthesis of inflammatory and 
fibrotic factors, resulting in tubulointerstial ischemia, inflammation, up-regulation of 
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oxidative stress and epithelial-to-mesenchimal transdifferentiation eventually culminating 
in fibrosis (Ruggenenti & Remuzzi, 2000; Mayer et al., 1993; Abbate et al., 1998; Fine et al., 
1998; Sánchez-Lozada et al., 2003; Higgins et al., 2007; Tian et al., 2008; Leh et al., 2011; 
Dussaule et al., 2011). The involvement of inflammation in the progression of CKD was 
widely demonstrated in experimental models of non-imunologic kidney disease 
(Bottinger & Bitzer, 2002; Müller, 2000, 2001; Fujihara, 1998, 2000; Romero et al., 1999; 
Mazzali et al., 2001; Eddy & Giachelli, 1995; Largo et al., 1999; Gómez-Garre et al., 2001; 
Zoja et al., 1998; Takase et al., 2003; Alvarez et al., 2002).  
Traditionally, the glomeruli have been in the centre of attention particularly in view of the 
hyperfiltration hypothesis involving the degradation and sclerosis of the remaining 
nephrons. However, the notion that tubulointerstitial fibrosis might rather cause than result 
from decreased glomerular function has gained strong evidence (Ong & Fine, 1994; Luft & 
Haller, 1995). Tubulointerstitial proliferation with incoming of inflammatory monocytes and 
macrophages, resulting from mechanical damage to the postglomerular interstitial 
vasculature, were also described, establishing the tubules and the interstitium as additional 
sites of early hypertensive damage (Eng et al., 1994). Furthermore, the up-regulation of the 
intrarrenal RAS, hypothetically mediated by local ischemia, is associated with increased 
expression of Angiotensin Converting Enzyme (ACE) in proximal tubules and peri-tubular 
interstitium. Here, ACE can cleave angiotensinogen and bradykinins creating an imbalance 
in favor of the former with the consequent stimulation of proliferation, fibrosis and salt 
retention (Carlos & Jeanneret, 2003).  
2.2 Epidemiology of hypertensive nephrosclerosis 
The general term “nephrosclerosis”, both benign and malignant, has been used to describe 
these lesions since the beginning of the 20th century. The causal relationship between 
malignant hypertension with fibrinoid necrosis and renal failure is consensual. On the other 
hand, the evidence for a relationship between milder degrees of hypertension and either 
benign nephrosclerosis and ESRD remains controversial (Zucchelli & Zuccala, 1995; 
Freedman et al., 1995; Kincaid-Smith, 1999). 
In the past 30 years, at the start of dialysis, an increasing number of patients have been 
labeled as having hypertension-related ESRD (USRDS 2003). Although, only few of them 
have undergone a kidney biopsy (Weisstuch & Dworkin, 1992) making it impossible to 
exclude other causes of ESRD, such as atheroembolic disease, ischemic nephropathy 
secondary to atheromatous disease, or glomerulonephritis (Zucchelli & Zuccala, 1998; 
Freedman et al., 1995). On the other hand, the increased life expectancy of the general 
population, due to better anti-hypertensive control and better survival from cardiovascular 
events, providing a longer time for hypertensive renal disease to progress, could in fact 
account for this increased prevalence (Caetano et al., 1999). The MRFIT study established a 
consistent relationship between increasing levels of systolic and diastolic blood pressure and 
ESRD that was independent of several other relevant variables. Nevertheless, several other 
literature reports originating in studies conducted in the US and in the United Kingdom 
concluded that benign nephrosclerosis did not significantly progress to ESRD (Tomson et 
al., 1999; Kincaid-Smith, 1982, 1999). However, the exception was provided by Africa-
American patients in whom a higher risk of progression to ESRD was widely demonstrated 
in all age groups (Rostand, 1982; Fogo, 1997; Marcantoni et al., 2002).  This disproportion 
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could not be explained by the higher prevalence and greater severity of hypertension in 
African-American patients or by socioeconomic determinants (Freedman 1993, 1995). 
Furthermore, in African-American patients progression for ESRD is faster across all levels of 
blood pressure (Klag et al., 1997; Shulman et al., 1989). Biopsy-proven hypertensive 
nephrosclerosis occurs earlier and is more severe in African-American than in Caucasian 
patients independently of blood presure values and proteinuria (Tracy et al., 1991; Perneger 
et al., 1995; Marcantoni et al., 2002). Traditionally, this excess of kidney damage has been 
associated with genetically or environmentally induced impairment of renal auto-regulation 
and amplification of profibrotic mechanisms (Campese et al., 1991; Duru et al., 1994; 
Suthanthiran et al., 1998).  
Early studies from animal models with Dahl salt-sensitive rats, Spontaneous Hypertensive 
Rats, Fawn-hooded rats and Brown and Norway rats as well as the results of the AASKD 
trial suggested a genetic susceptibility to hypertensive vascular damage (Brown et al., 1996; 
Churchill et al., 1997; Freedman et al., 1998; Zarif et al., 2000; Agodoa et al., 2001). Several 
genetic alterations have been associated to a more rapid decline of renal function in African-
American patients with hypertensive nephrosclerosis. Polymorphisms of the kallikrein 
(KLK1) gene promoter were associated with a higher risk of ESRD in the presence of 
hypertension in a population of African-American patients (Yu et al., 2002). Different 
genetic polymorphisms of the RAS have been linked to a greater progression to ESRD across 
a wide spectrum of populations and causes of CKD (Wong et al., 2008). Polymorphisms of 
TGF-ǃ have also been implicated in hypertension and progressive fibrosis (August et al., 
2000). Non-muscle myosin heavy chain 9 gene (MYH9) polymorphisms, leading to 
disruption of normal podocyte function, brought attention to the role of podocyte injury as a 
mechanism of kidney damage in hypertensive glomerulosclerosis (Freedman et al., 2009). 
Genetic variation within the loci of the adrenergic beta-1 receptor (ADRB1) gene is associated 
with increased adrenergic activity and an increased risk of progressive renal disease (Fung et 
al., 2009). Specific polymorphisms in the C - reactive protein gene predicted a higher risk for 
CKD progression, resistant to the action of ACE inhibitors in African-American patients (Hung 
et al., 2010). Finally, mutations in the human methylenetetrahydrofolate reductase (MTHFR) 
gene were associated with elevated levels of homocysteine and a faster decline of renal 
function over time in African-American patients (Fung et al., 2011). Very recently a study, 
conducted in a population of Hispanic descent reported an association between 
polymorphisms of vascular endothelial growth factor (VEGF) and hypertensive nephropathy 
with subsequent progression to ESRD (Yang et al., 2011).  
3. Pathogenesis of hypertension in chronic kidney disease  
Although the kidney is also involved in essential or primary hypertension, its insufficiency 
causes high BLOOD PRESSURE, contributing to 2-5 % of all cases of hypertension or half 
the cases of all forms of secondary hypertension (Kaplan, 2006b). The pathogenesis of 
hypertension-related to CKD is complex and multifactorial, mainly in the late stages of the 
renal disease. In addition to the classical factors, such as increased intravascular volume and 
excessive activity of the RAS, there are new recognized players such as increased activity of 
the sympathetic nervous system, endothelial dysfunction and alterations of several humoral 
and neural factors that promote an increase of the blood pressure. Hypertension is highly 
prevalent in CKD, being related with the level of renal function, the etiology of the kidney 
disease and the age of the patient. Patients with vascular disease, diabetes and polycystic 
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kidney disease (PKD) are more prone to be hypertensive (Ridao et al., 2001). It is also known 
that as renal function worsens the prevalence of hypertension increases. Therefore, more 
than 80 % of the patients beginning renal replacement therapy have high blood pressure 
(Ridao et al., 2001, USRDS, 2010). 
3.1 Sodium and volume status 
The fundamental role of the kidney in the control of sodium and volume homeostasis is well 
acknowledged since the seminal studies of Dahl and Guyton. During the last decades, a 
bulk of evidence shows that volume expansion is the first and major pathogenic mechanism 
for hypertension in CKD. In the early stages of CKD, patients have already an increased 
exchangeable sodium and blood volume, which are correlated with the blood pressure level 
(Beretta-Piccoli et al, 1976).  
According to the Guyton’s whole-body auto-regulation concept, many organs, including the 
kidney and the brain, have the ability to maintain a relatively constant blood flow in the 
presence of variations of the perfusion pressure (Coleman & Guyton, 1969). Guyton 
proposed that this auto-regulation could be responsible for the secondary increase of the 
peripheral resistance in the presence of blood volume expansion, as it occurs in CKD 
(Guyton et al, 1980). Therefore, initially, an augment of the blood volume increases the 
cardiac output and simultaneously the peripheral vascular resistance fell. Later, the auto-
regulatory increase of the vascular resistance causes a pressure natriuresis (Navar, & Majid, 
1996), with normalization of the cardiac output and maintenance of high blood pressure 
values.  
3.2 The Renin-Angiotensin System 
The relevance of the RAS, in physiological terms, is based on its capacity to regulate arterial 
pressure and sodium balance. When the blood pressure or perfusion fall, or the sympathetic 
activity increases, the juxtaglomerular cells secrete renin, which cleaves angiotensinogen, 
leading to an increase in angiotensin II (AII) levels. This octapeptide is a powerful 
vasoconstrictor and stimulates the production of aldosterone, which, in turn, increases renal 
sodium reabsorption, and closes the regulatory feedback loop. However, if the blood 
volume is normal, the increased activity of the RAS produces an abnormal rise in the blood 
pressure.  
Only a small proportion of CKD patients have a measurable increase of the RAS (Acosta, 
1982). However, this activity in most of these patients is inappropriately high in the volume-
expanded milieu of CKD (Davies et al, 1973; Mailloux, 2001). Furthermore, in CKD, mainly 
secondary to vascular disease, diabetes or PKD, in areas of renal injury or ischemia there is a 
greater production of local and intra-renal AII which then exacerbates systemic 
hypertension (Acosta, 1982;Rosenberg et al, 1994).  
3.3 Oxidative stress and nitric oxide antagonism 
“Oxidative stress is an imbalance between oxidants and anti-oxidants in favor of the 
oxidants, potentially leading to damage”( Sies, 1997). In CKD there is an excess of oxidant 
molecules such as superoxide and hydrogen peroxide and a decrease of anti-oxidant ones, 
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such as catalase, superoxide dismutase and glutathione dismutase (Vaziri et al., 2002). The 
excess of reactive oxygen species may directly stimulate vascular contraction or reduce nitric 
oxide, contributing to hypertension in CKD (Hu et al., 1998). In addition, it is known that 
anti-oxidant agents can reduce the blood pressure in animal models of hypertension (Vaziri 
et al., 1997). The endothelial-derived nitric oxide has the capacity to maintain the vascular 
tone and to produce vasodilatation, through the activation of guanylate cyclase. In CKD, 
there is an increase of asymmetric dimethylarginine, an inhibitor of nitric oxide synthase 
(Leone et al., 1992). Moreover, has we pointed out before, the increase amount of reactive 
oxygen species in CKD impair nitric oxide effects. These two factors are responsible for a 
decrease nitric oxide activity in CKD which contribute to endothelial dysfunction and 
increased blood pressure.  
3.4 Sympathetic Nervous System and Renal Dopaminergic System 
The Sympathetic Nervous System activity is increased in CKD, as was demonstrated almost 
20 years ago (Converse et al., 1992). Afferent signals from the diseased kidney are 
transmitted to the vasomotor control center in the brain increasing the blood pressure 
(Rump et al, 2000). In addition, increased plasma noradrenaline levels are often high in CKD 
patients. Evidence for the role of sympathetic nervous system is provided by the fall of 
blood pressure after renal sympathetic denervation or after bilateral nephrectomy (Khawaja 
et al, 2011).  
Dopamine, a precursor of noradrenaline, has a natriuretic effect by inhibiting Na-K-ATPase 
in proximal tubular segments. Patients with CKD have reduced urinary excretion of 
dopamine (Casson et al, 1983) and decreased activity of the renal dopaminergic system, 
which correlates well with the degree of renal dysfunction (Pestana et al, 2001). These data 
show that the reduced activity of renal dopaminergic system in CKD, by decreasing the 
sodium excretion, may be another factor connected with the hypertension of CKD.  
3.5 Miscellaneous 
Endothelin is a family of four 21 amino acid peptides and ET-1, the predominant isoform, is 
produced by endothelial cells. It can mediate vasoconstriction when binds to its A and B 
receptors in vascular smooth muscle cells. Vasodilation results from the interaction with the 
B receptor in endothelial cells. In CKD, endothelin levels are increased and the use of 
selective endothelin A receptor antagonist produces reduction of blood pressure associated 
with renal vasodilatation (Goddard et al, 2004).  
Parathormone starts to rise early in CKD. Its role in the pathogenesis of hypertension 
remains controversial. It has been shown, by some but not all authors that the parathormone 
can increase intracellular calcium and aggravate hypertension and that parathyroidectomy 
may improve blood pressure control.  
The role of Endogenous Digitalis–like Factors (EDLFs) in sodium or volume dependent 
hypertension was elucidated only recently, after several decades of intense research. The 
EDLFs include quite a few substances, produced in the adrenal gland or in the 
hypothalamus, that inhibit the Na-K-ATPase in cell membranes, being at the same time 
natriuretic and vasoconstrictors (Takahashi et al, 2011). The high levels of EDLFs in CKD 
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(Hamlyn et al, 1996; Komiyama et al, 2005), secondary to an increased sodium content and 
expanded blood volume, may also contribute to the hypertension commonly seen in this 
population.  
4. Considerations about hypertension treatment in CKD 
The treatment of hypertension in CKD has three main goals: blood pressure control; 
delaying the progression of CKD itself; decreasing the risk of cardiovascular complications 
in this particular population. The role of non-drug therapy is frequently underestimated. 
However, salt restriction and lifestyle modifications are invaluable to achieve the goals 
defined above. Drug therapy is fundamental, and at later stages of CKD, double or multiple 
drug associations are often needed. RAS antagonists should the preferred drugs and their 
association with diuretics mandatory.  
4.1 Salt restriction and life style modifications 
Given that one of the main causes of CKD related hypertension is increased extracellular 
volume (or exchangeable sodium), dietary sodium restriction makes every sense. Excess 
dietary salt, typical of Western Countries, is clearly associated with the massive number of 
hypertensive patients in modern societies and, in the other extreme, it is well known that in 
primitive civilizations with low sodium intake, the prevalence of hypertension is irrelevant 
(Carvalho et al, 1989). Guidelines on CKD recommend a low sodium ingestion (70– 
100mmol/day) in patients with CKD (KDOQI, 2004; Joint Specialty Committee Guidelines, 
2006; Levin et al, 2008). This suggestion is based on the evidence that a lower sodium intake 
is associated with a reduction of the blood pressure values (Sacks et al, 2001), increases the 
protective effect of ACE inhibitors in patients with proteinuria (Heeg et al, 1989) and, 
possibly, declines the progression of renal failure (Ciancaruso et al, 1998). Concerning life 
style changes, it is recommended to CKD patients to have a healthy life. Cigarette smoking, 
a well known cardiovascular risk factor also works as a renal risk factor. Smoking increases 
blood pressure by stimulating the sympathetic nervous system and also by rising plasma 
endothelin levels (Orth, 2003; Halimi & Mimran, 2000). The related excessive production of 
oxygen-free radicals can produce endothelial dysfunction and consequently be another 
factor implicated in the increase of blood pressure. It is critical to stop smoking, because this 
preventable risk factor can hasten the progression of chronic renal insufficiency in diabetic 
and non-diabetic nephropathies, independently of gender and race (Orth, 2003). Reduction 
of alcohol ingestion is also another useful decision, not because it is related with worsening 
of the renal function itself, but rather because it can be associated with smoking and obesity 
(Suter & Schutz, 2008). Weight loss in hypertensive obese patients is associated with 
reductions of the blood pressure, proteinuria and left ventricular hypertrophy, with benefits 
in terms of total cardiovascular outcomes. In CKD patients a favorable impact was also 
demonstrated: a decrease in proteinuria and better blood pressure control (Praga & Morales, 
2006). Weight reduction may improve insulin resistance and decreases inflammation and 
oxidative stress beyond positive actions on the RAS and sympathetic nervous system. 
Furthermore, it may also slow down the progression to ESRD. The regular practice of 
exercise also has a beneficial effect on CKD patients. A high-quality exercise program can 
improve many indicators of physical performance, as well as all cardiovascular indices. 
Exercise may improve the control of blood pressure and endothelial function and decrease 
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inflammation and insulin resistance (Johansen, 2007). Moreover, physical exercise has no 
untoward effect on progression of CKD. However, since this population has a potential 
bigger risk of musculoskeletal injuries and cardiac events it is mandatory to perform an 
accurate medical checkout before enrolling any exercise program.  
4.2 Pharmacological therapy 
The need to employ anti-hypertensive drugs mainly in the late stages of the disease is 
mandatory in almost all CKD patients. It is, often, necessary to use multiple drug regimens 
to control the blood pressure levels adequately and a constant evaluation of patient 
compliance and frequent medical reassessment meetings are required. 
4.2.1 What should be the target blood pressure? 
Nearly all guidelines concerning CKD patients support that blood pressure should be 
targeted to less than 130/80 mmHg (Chobanian et al, 2003; KDOQI, 2004; Levin et al, 2008). 
Despite major well designed randomized controlled trials (RCT) (Klahr et al, 1994; Estacio et 
al, 2000; Wright et al, 2002; Ruggenenti et al, 2005), there is no clear evidence that a blood 
pressure target < 130/80 mmHg is better, in terms of renal disease progression in CKD 
patients. A recently published systematic review did not show any advantage, regarding 
progression of CKD, in keeping blood pressure < 130/80 mmHg (Upadhyay et al, 2011). 
Post-hoc analysis of the MDRD and ABCD studies showed some benefits in the group of 
patients with a better control of the blood pressure, and two meta-analyses (Makki et al, 
1995; Casas et al, 2005) also showed a protracted progression of the CKD in patients with 
lower blood pressure levels. Furthermore, another meta-analysis including 11 RCT with 
non-diabetic CKD patients, showed that those with systolic blood pressure between 110-119 
mmHg, had the lowest risk of progression of CKD, and that this risk was greatly increased 
in patients with systolic blood pressure > 130 mmHg (Jafar et al, 2003). Finally, Appel and 
co-workers demonstrated that in African-American patients with CKD and proteinuria, 
intensive blood pressure treatment decreased the risk of progression of renal failure (Appel 
et al, 2010). Secondary analysis from large RCT with antagonists of the RAS, such as the 
HOPE, IDNT and ADVANCE studies, proved that hypertension treatment in CKD patients 
can reduce the risk of cardiovascular events (Mann et al, 2001; Pohl et al, 2005; Heerspink et 
al, 2010). However, insofar no RCT was able to prove that a blood pressure < 130/80 mmHg 
is better in terms of cardiovascular outcomes. On the other hand, it must be kept in mind 
that lowering the blood pressure < 120/70 mmHg, mainly in older patients, can increase the 
progression of renal failure (van Bemmel et al, 2006) and enhance the probability of a 
cardiovascular event (Pohl et al, 2005; Hirsh et al, 2008). In brief, there is no strong evidence 
to have a blood pressure target < 130/80 mmHg, and we should maintain the goal of blood 
pressure < 140/90 mmHg, mostly in the elderly. However, in patients under 60 years with 
proteinuria a lower target might be allowed.  
4.2.2 Which anti-hypertensive drug must we choose? 
We must choose a drug to control the blood pressure, with the ability to slow down the 
inexorable progression of CKD and decrease the cardiovascular risk of this population. 
Hypertension control, by itself, can delay the progression of CKD, as Mogensen reported 
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more than 30 years ago, using diuretics and a Beta Blocker in type I diabetic patients with 
nephropathy (Mogensen, 1976). Notwithstanding, in the last decades, the superiority of the 
ACE  inhibitors, and lately of the angiotensin receptor blockers (ARB), in terms of 
preventing the progression of CKD and also in terms of reducing cardiovascular morbidity 
and mortality have been widely reported in medical literature. The benefits of ACE 
inhibitors and ARB are far beyond and independent of blood pressure control. The 
mechanisms of renal protection result from hemodynamic and non-hemodynamic actions: 
decrease of intraglomerular hydrostatic pressure, decrease of protein excretion, and 
decrease of AII activity (Sica, 2003). This octapeptide is also a powerful cytokine with non-
hemodynamic properties such as proinflammatory and profibrotic actions. AII upregulates 
the production of adhesion molecules, cytokines and chemokines, increasing the number of 
inflammatory cells in the kidney. It also stimulates extracellular matrix accumulation 
through the production of profibrotic factors, such as transforming growth factor-ǃ. The 
decrease of AII activity observed with these drugs explains, in part, the extra advantages of 
their use in CKD patients. Several RCT and meta-analysis, in type 1 and 2 diabetic patients 
as well as in non-diabetic patients, confirmed that ACE inhibitors and ARB must be first 
choice drugs in renal patients, since they effectively slow the progression of CKD (Jafar et al, 
2003; Lewis et al, 1993; Lewis et al, 2001; Brenner et al, 2001; Jafar et al, 2001). In addition, these 
particular drugs have the ability to reduce cardiovascular morbidity and mortality. In a post 
hoc analysis of the HOPE study, treatment with ramipril in patients with slight to moderate 
CKD decreased significantly the number of cardiovascular events (Mann et al, 2001). In the 
PEACE trial, trandolapril reduced the mortality in 27 % only in the subgroup of patients with 
renal insufficiency (Solomon et al, 2006) and in a recent meta-analysis, Balamuthusamy and co-
workers found that RAS blockade in patients with non-diabetic renal disease was associated 
with a significant reduction in cardiovascular outcomes (Balamuthusamy et al, 2007). 
Concerning the secondary effects of these anti-hypertensive agents in renal patients, special 
attention must be given to: possible slight increase of the creatinine level (< 25 %), reflecting a 
decrease of the glomerular hyperfiltration, which means good news on the long run; a major 
increase of the creatinine level is suggestive of volume depletion (concomitant use of diuretics) 
or of bilateral renal artery stenosis; hyperkalemia is usually insignificant, but when severe it 
might be fatal; we must be aware of the potassium intake and of the use of other potentially 
hyperkalemic drugs, like aldosterone antagonists or non-steroid anti-inflammatory drugs; 
finally, we must also take into consideration that these drugs may also increase the need for 
higher dose of erythropoiesis stimulating agents (Neves et al, 2007).  
4.2.3 Which drug association must we favor? 
As stated previously, most patients will need two or more drugs to control hypertension 
and a stepwise approach should be pursued. After the prescription of an ACE inhibitor or 
an ARB, if there are no contra-indications, the choice of another anti-hypertensive agent 
must be dictated by any specific conditions of each patient. Diuretics are very useful and 
almost always mandatory, mainly in later stages of the disease, because of the presence of 
fluid overload. Thiazides can be used when the GFR > 30 ml/min/1,73 m2 body surface area, 
being ineffective beyond this level. Then, we should rather use a loop diuretic such as 
indapamide or furosemide (KDOQI, 2004). Diuretics have the ability to diminish sodium 
reabsorption, thereby reversing hypervolemia and reducing the blood pressure. By reducing  
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the blood volume and stimulating the renin activity, diuretics intensify the effect of ACE 
inhibitors and ARB. Potassium sparing agents must be avoided or used very carefully due 
to the risk of life threatening hyperkalemia, particularly if the patient is also under an ACE 
inhibitor or ARB (KDOQI, 2004). For all these reasons, in the CKD patient, diuretics should 
be the first class of anti-hypertensive drugs to be added to an ACE inhibitor or an ARB. 
Calcium Channel Blockers (CCB) are potent vasodilators and also have a relevant role in the 
control of the blood pressure in CKD patients. They are particularly indicated if the patient 
has angina or heart failure secondary to diastolic dysfunction (KDOQI, 2004). Due to distinct 
renal hemodynamic effects, the type CCB to use should not be indiscriminate. In fact, 
dihydropyridines by inhibiting the renal auto-regulatory capacity and by increasing the 
glomerular permeability, intensifying proteinuria (Nathan et al, 2005), are harmful in terms 
of CKD progression. This observation was well demonstrated in the AASK and IDNT trials 
(Wright et al, 2002, Lewis et al, 2001), where the dihydropyridine amlodipine was worse 
than the ACE inhibitor or the ARB regimen. However, the non-dihydropyridines, do not 
interfere with glomerular auto-regulation, and therefore do not exhibit deleterious effect in 
terms of proteinuria and renal function (Nathan et al, 2005; Bakris et al, 1996). In renal 
patients with proteinuria, the non-dihydropyridine CCB are a good choice to add to an ACE 
inhibitor to an ARB. On the contrary, they should be avoided in patients with second and 
third degree heart block or with congestive heart failure due to systolic dysfunction 
(KDOQI, 2004). Once the dihydropiridines have detrimental effects on renal function, it is 
recommended that they must be given in combination with kidney protecting drugs, such as 
the AII antagonists. In fact, in the ACCOMPLISH trial, the risk of progression of the CKD 
was lower in the group of patients treated with a combination of an ACE inhibitor with 
amlodipine than in the group treated with the ACE inhibitor and a diuretic (Bakris et al, 
2010).. This study may support, at least in some patients, the use of a CCB as the first drug to 
add to an AII axis antagonist. It has been shown that this association may have a greater 
anti-inflammatory effect. Beta-Adrenergic Blockers comprise a heterogeneous group of 
drugs organized in classes according to their receptor selectivity, lipid-solubility, intrinsic 
sympathetic activity and membrane stabilizing capacity (Kaplan, 2006a). The use of a Beta-
Adrenergic Blocker, in a renal patient, is almost always justified by the coexistence of 
ischemic heart disease. This class of drugs is specially indicated in patients with prior angina 
or myocardial infarction or with atrial tachycardia or fibrillation (KDOQI, 2004). The water 
soluble Beta-Adrenergic Blockers (atenolol, sotalol) are excreted by the kidney and may 
accumulate in CKD; the lipid soluble ones (propranolol, metoprolol) are metabolized in the 
liver and may be associated with central nervous system side effects. Both types can cause 
hyperkalemia. Beta-Adrenergic Blockers do not worsen renal function but, beyond blood 
pressure control, they do not protect the kidney (Hannedouche et al, 1994). Carvedilol is a 
Beta-Adrenergic Blocker with non-selective ǂ1 activity that displays some advantages: 
beneficial effects on lipid profile (Stafylas & Sarafidis, 2008), increase of insulin sensitivity, 
and the capacity to reduce albumin excretion (Bakris et al, 2004). Respecting renal 
hemodynamics, carvedilol preserves the renal blood flow and the glomerular filtation rate 
(GFR), whereas decreases the renal vascular resistance. Furthermore, has anti-oxidant 
activity. Contradictory results concerning the favorable effect of Beta-Adrenergic Blocker on 
cardiovascular morbidity and mortality of CKD patients have been reported in medical 
literature. Prospective RCT are needed to ascertain whether these anti-hypertensive drugs 
really do have a positive influence on the survival of renal patients or not. Aldosterone 
antagonists can be used in renal patients, but with great caution if the GFR is below 30 
ml/min, the patient is taking an ACE inhibitor or an ARB, or has additional risk factors for 
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hyperkaliemia. The association of aldosterone antagonists with AII antagonists is justified by 
the called aldosterone escape phenomenon. The hypothetical advantage of this add-on therapy 
is attributed to the anti-fibrotic and anti-hypertensive properties of aldosterone antagonists. 
Although there are some beneficial effects in terms of proteinuria , the addition of an 
aldosterone antagonist to an ACE inhibitor or to an ARB does not slow the progression of 
renal failure. Besides, the risk of hyperkalemia is markedly increased. Renin Inhibitors, a new 
class of antagonists of the RAS that blocks the conversion of angiotensinogen to angiotensin I, 
have recently started to be used worldwide. Aliskiren, the first compound of the class, shows 
an effective blood pressure control and reduces albuminuria successfully in type 2 diabetic 
patients, when given alone (Persson et al, 2009) or in combination with losartan (Parving et al, 
2008). This renoprotection is independent of its blood pressure lowering effect. Further studies 
are needed to determine if aliskiren, alone or in association, is able to reduce hard renal and 
cardiovascular end-points in CKD patients. The utilization of ǂ-adrenergic agents or the potent 
vasodilator minoxidil is only justified if blood pressure control was still not achieved with the 
previous described classes of anti-hypertensive drugs. They are extremely potent agents but 
present many adverse side effects. Furthermore, minoxidil must always be associated with a 
Beta-Adrenergic Blocker and a diuretic in order to control the reflex tachycardia and the fluid 
retention induced by the former (KDOQI, 2004). 
4.2.4 What about the dual blockade of the RAS? 
The rational for using two antagonists of the RAS is sustained by the existence of the AII 
escape phenomenon. After long-term ACE inhibition, it was demonstrated that AII 
synthesis via non-ACE pathways increases. Moreover, there are some limitations of ACE 
inhibitors in decreasing the local production of AII (Arici & Erdem, 2009). The ARB blocks 
the binding of AII to its receptors, reducing both its systemic and local effects (Arici & 
Erdem, 2009). There are advantages and drawbacks of combination therapy (Wolf & Ritz, 
2005), but, in clinical terms, the aim of combination therapy is to block of the RAS more 
effectively (Arici & Erdem, 2009). Although several studies showed a greater decrease of 
albuminuria with the dual blockade (Mogensen et al, 2000; Campbell et al, 2003; Jennings et 
al, 2007), there are no RCT demonstrating a true slow down of CKD with combination 
therapy. In the ONTARGET study, the group of patients under ramipril plus telmisartan 
presented a higher renal impairment - doubling of serum creatinine or dialysis - and there 
were no differences in respect to cardiovascular outcomes (Yusuf et al, 2008). The ValHeFT 
and the VALIANT studies also showed more kidney dysfunction in the combination groups 
(Conn et al, 2001; Pfeffer et al, 2003), despite better cardiovascular results in the ValHeFT 
(Conn et al, 2001). In summary, concerning CKD progression, despite the theoretical 
advantages of combination therapy, presently there are no RCT demonstrating such benefit. 
Furthermore, the dual blockade is not harmless, and is associated with the risk of 
hyperkalemia and of greater renal impairment. Probably, studies with selected patients 
(with proteinuria > 1g/24h) or a different type of dual blockade with a renin inhibitor, will 
demonstrate a clear superiority of an association of two antagonists of the RAS. At the 
moment this association cannot be recommended.  
5. Conclusion 
Hypertension and CKD are both the chicken and the egg in this story. CKD resulting from 
hypertension and hypertension resulting from CKD are complex and multifactorial. A better 
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understanding of the physiopathology mechanisms is imperative to improve our treatment 
strategies and reduce renal and cardiovascular adverse events. After decades of intense 
basic and clinical research in this area many questions remain unanswered: Is essential 
hypertension a cause of CKD in Caucasians? Which is the prevalent physiopathological 
mechanisms underlying CKD related hypertension in a particular patient? Which is the 
better anti-hypertensive therapy in our CKD patients and particularly in a specific patient? 
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